Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29678818 | 1.00 | DRD2 (0.64) | DRD2 | |
| SCHEMBL1037463 | 0.96 | DRD2 (0.62) | DRD2 | |
| SCHEMBL4328789 | 0.95 | DRD2 (0.60) | DRD2 | |
| SCHEMBL22129342 | 0.93 | DRD2 (0.67) | DRD2 | |
| SCHEMBL22163345 | 0.88 | DRD2 (0.62) | DRD2 | |
| SCHEMBL20512966 | 0.80 | DRD2 (0.81) | DRD2 | |
| SCHEMBL29786463 | 0.80 | DRD2 (0.81) | DRD2 | |
| SCHEMBL1036238 | 0.80 | MEN1 (0.62) | DRD2 | |
| SCHEMBL31438780 | 0.80 | MEN1 (0.62) | DRD2 | |
| SCHEMBL20512980 | 0.79 | DRD2 (0.81) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113195454-B | Preparation method of amide-like derivative and intermediate thereof | 江苏恩华药业股份有限公司 | 2022-05-24 | — | — | CN | disclosed |
| US-20220048887-A1 | IMPURITIES OF AMIDE-LIKE DERIVATIVES AND USE THEREOF | NHWA PHARMA. CORPORATION (CN) | 2022-02-17 | — | — | US | disclosed |
| US-20220048887-A1 | IMPURITIES OF AMIDE-LIKE DERIVATIVES AND USE THEREOF | NHWA PHARMA. CORPORATION (CN) | 2022-02-17 | — | — | US | disclosed |
| EP-3901149-A1 | IMPURITIES OF AMIDE DERIVATIVES AND USE THEREOF | NHWA Pharma Corporation (CN) | 2021-10-27 | — | — | EP | disclosed |
| EP-3901149-A1 | IMPURITIES OF AMIDE DERIVATIVES AND USE THEREOF | NHWA Pharma Corporation (CN) | 2021-10-27 | — | — | EP | disclosed |
| CN-113195454-A | Preparation method of amide-like derivative and intermediate thereof | 江苏恩华药业股份有限公司 | 2021-07-30 | — | — | CN | disclosed |
| CN-113195486-A | Impurities of amide derivatives and application thereof | 江苏恩华药业股份有限公司 | 2021-07-30 | — | — | CN | disclosed |
| US-20210113556-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-04-22 | — | — | US | disclosed |
| US-20200237755-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-07-30 | — | — | US | disclosed |
| WO-2020125580-A1 | IMPURITIES OF AMIDE DERIVATIVES AND USE THEREOF | 江苏恩华药业股份有限公司 | 2020-06-25 | — | — | WO | disclosed |
| US-20140163039-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-06-12 | — | — | US | disclosed |
| US-8618109-B2 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PARMACEUTICAL CO., LTD. (JP) | 2013-12-31 | — | — | US | disclosed |
| US-20130158044-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-06-20 | — | — | US | disclosed |
| US-8349840-B2 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-20110152286-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. | 2011-06-23 | — | — | US | disclosed |
| US-7888362-B2 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-02-15 | — | — | US | disclosed |
| EP-1869025-B1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMA CO LTD (JP) | 2011-01-26 | — | — | EP | disclosed |
| US-20100179322-A1 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-07-15 | — | — | US | disclosed |
| EP-1869025-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006112464-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179322-A1 | Piperazine-substituted benzothiophenes for treatment of mental disorders | GRIN2C, TPH1, HTR2C | DRD2 126/4885 |
| US-20200237755-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | DRD2 126/4885 |
| US-20140163039-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | GRIN2C, TPH1, HTR2C | DRD2 126/4885 |
| US-20130158044-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | GRIN2C, TPH1, HTR2C | DRD2 126/4885 |
| US-20210113556-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | DRD2 126/4885 |
| US-20220048887-A1 | IMPURITIES OF AMIDE-LIKE DERIVATIVES AND USE THEREOF | NOTUM, CYP51A1, HADHB | DRD2 2480/4885 |
| US-20110152286-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | GRIN2C, TPH1, HTR2C | DRD2 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.